US2022054715A1PendingUtilityA1

Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto

Assignee: UNIV EMORYPriority: Sep 19, 2011Filed: Nov 10, 2021Published: Feb 24, 2022
Est. expirySep 19, 2031(~5.1 yrs left)· nominal 20-yr term from priority
A61K 31/436A61L 27/52A61K 31/4745A61K 31/56A61L 27/24A61K 31/404A61P 19/00A61K 31/506A61K 31/232A61K 31/4174A61K 31/136A61K 31/475A61L 27/46A61K 38/39A61L 27/12A61K 33/42A61K 31/585A61L 2300/414A61K 31/4184A61K 31/196A61K 31/7068A61K 31/203A61L 2430/02A61K 38/1875A61K 31/07A61K 31/704A61L 2300/45A61K 31/5377A61K 31/7048A61K 31/407A61L 27/54A61K 31/05
75
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

Claims

exact text as granted — not AI-modified
1 . A method of forming bone in vivo comprising implanting a graft composition comprising a collagen matrix and tacrolimus in a subject such that bone forms in the graft. 
     
     
         2 . The method of  claim 1 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3  of bone graft volume. 
     
     
         3 . A method of forming bone in vivo comprising implanting a graft composition comprising a hydrogel matrix and tacrolimus in a subject such that bone forms in the graft. 
     
     
         4 . The method of  claim 3 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3  of bone graft volume. 
     
     
         5 . A method of forming bone in vivo comprising implanting a graft composition comprising calcium phosphates and tacrolimus in a subject such that bone forms in the graft. 
     
     
         6 . The method of  claim 5 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3  of bone graft volume. 
     
     
         7 . The method of  claim 5 , wherein said calcium phosphates are hydroxyapatite and tricalcium phosphate. 
     
     
         8 . A method of performing spinal fusion comprising implanting a bone graft composition comprising collagen matrix and tacrolimus in a subject such that bone forms in the graft between two vertebrae of a subject. 
     
     
         9 . The method of  claim 8 , wherein the subject has symptoms of back pain. 
     
     
         10 . The method of  claim 8 , wherein the subject is diagnosed with a degenerative disc. 
     
     
         11 . The method of  claim 8 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3  of bone graft volume. 
     
     
         12 . A method of performing spinal fusion comprising implanting a bone graft composition comprising hydrogel matrix and tacrolimus in a subject such that bone forms in the graft between two vertebrae of a subject. 
     
     
         13 . The method of  claim 12 , wherein the subject has symptoms of back pain. 
     
     
         14 . The method of  claim 13 , wherein the subject is diagnosed with a degenerative disc. 
     
     
         15 . The method of  claim 12 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3  of bone graft volume. 
     
     
         16 . A method of performing spinal fusion comprising implanting a bone graft composition comprising calcium phosphates and tacrolimus in a subject such that bone forms in the graft between two vertebrae of a subject. 
     
     
         17 . The method of  claim 16 , wherein the subject has symptoms of back pain. 
     
     
         18 . The method of  claim 16 , wherein the subject is diagnosed with a degenerative disc. 
     
     
         19 . The method of  claim 16 , wherein more than 0.7 mg of tacrolimus is present per 150 mm 3  of bone graft volume. 
     
     
         20 . The method of  claim 16 , wherein said calcium phosphates are hydroxyapatite and tricalcium phosphate said calcium phosphates are hydroxyapatite and tricalcium phosphate.

Join the waitlist — get patent alerts

Track US2022054715A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.